Clinical Trials
10 trialsNCT05003141 2022-03-28
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Phase 1 Unknown
NCT03999697 2019-06-27
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT00004036 2013-12-19
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00769613 2013-12-18
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00009776 2013-09-20
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00023816 2013-09-20
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00324597 2013-09-17
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00008021 2013-08-07
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00935597 2010-10-29
Host Dendritic Cells in Allograft Patients
Icahn School of Medicine at Mount Sinai
Phase 1 Unknown
NCT00004086 2009-06-09
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
National Cancer Institute (NCI)
Phase 1 Unknown